Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[HCV-serotype and IFN response]

H Nakamura1, M Kako, T Aikawa

  • 1Fourth Dep. of Internal Medicine, Teikyo University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Semidiscoid lateral meniscus].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same author

[Abnormal chest shadow on CT in immunosuppressed patients].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same author

[MR imaging evaluation of plica synoviallis mediopatellaris of the knee joint].

Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica·1992
Same author

Structure-activity relationships of mu-conotoxin GIIIA: structure determination of active and inactive sodium channel blocker peptides by NMR and simulated annealing calculations.

Biochemistry·1992
Same author

Tumor necrosis factor modulation of expression of the cystic fibrosis transmembrane conductance regulator gene.

FEBS letters·1992
Same author

Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E peptide fragments.

FEBS letters·1992
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Hepatitis C virus (HCV) serotype 2 and genotype III are linked to better response rates in chronic hepatitis C patients treated with interferon-alpha (IFN-alpha). Identifying HCV serotypes and genotypes aids in predicting treatment outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Context:

  • Chronic hepatitis C (HCV) infection affects millions globally.
  • Interferon-alpha (IFN-alpha) is a standard treatment for chronic hepatitis C.
  • Predicting treatment response is crucial for optimizing patient management.

Purpose:

  • To investigate the association between Hepatitis C virus (HCV) serotypes and genotypes and the response to interferon-alpha (IFN-alpha) therapy.
  • To determine if HCV serotyping and genotyping can predict treatment outcomes in chronic hepatitis C patients.

Summary:

  • A study of 114 chronic hepatitis C patients treated with IFN-alpha examined the relationship between HCV serotypes and treatment response.
  • Patients with HCV serotype 2 showed significantly higher response rates (20/33) compared to serotype 1 (5/35).

Related Experiment Videos

  • HCV genotype III (78.3% response) and serotype 2 (85.7% response) were associated with better IFN-alpha treatment outcomes than genotype II and serotype 1.

    • Impact:

    • HCV serotyping and genotyping are valuable tools for predicting IFN-alpha treatment response in chronic hepatitis C.
    • These findings can help clinicians personalize treatment strategies for hepatitis C patients.
    • Improved prediction of treatment response may lead to better patient outcomes and reduced healthcare costs.